Evidence map›Paper›PMID 42577016›Full record

ArticleJAC-antimicrobial resistance2026

Cesar Copaja-Corzo, Carlos Mazza-Diaz, Carlos Tairo-Cerron, Roxana Sandoval-Ahumada, José Ballena-López, Javier Flores-Cohaila, Brayan Miranda-Chavez, Giancarlo Pérez-Lazo

Abstract read
In one paragraph

Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cesar Copaja-CorzoUnidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Perú.ORCID https://orcid.org/0000-0002-3497-0158
Carlos Mazza-DiazServicio de Infectología, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Perú.ORCID https://orcid.org/0009-0006-0280-547X
Carlos Tairo-CerronServicio de Infectología, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Perú.ORCID https://orcid.org/0009-0002-3676-243X
Roxana Sandoval-AhumadaDepartamento de Patología Clínica, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Perú.ORCID https://orcid.org/0000-0002-6671-2778
José Ballena-LópezServicio de Infectología, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Perú.ORCID https://orcid.org/0000-0001-6936-6287
Javier Flores-CohailaEscuela de Postgrado, Universidad Continental, Huancayo, Perú.ORCID https://orcid.org/0000-0002-9169-2094
Brayan Miranda-ChavezCentro de Estudios e Investigación en Educación Médica y Bioética, EDUCAB-UPT, Facultad de Ciencias de la Salud, Universidad Privada de Tacna, Tacna, Perú.ORCID https://orcid.org/0000-0001-9035-3317
Giancarlo Pérez-LazoServicio de Infectología, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Perú.ORCID https://orcid.org/0000-0003-3823-4737

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To identify predictors of all-cause 30-day mortality in bloodstream infections (BSI) caused by carbapenem-susceptible Methods: This was a single-centre retrospective cohort study of adults with a first episode of BSI due to carbapenem-susceptible Results: Of the 403 patients (median age 66 years, 55.8% men; 58.6% ESBL+), 83 (20.6%) died. Mortality was higher in patients with Conclusions:

Identifiers

PMID42577016
PMCPMC13453535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.